Hundreds of rural hospitals are at risk of closing, threatening critical care
Hundreds of hospitals in rural parts of the United States are in danger of closing because they can no longer afford to stay open, according to a new report from the Center for Healthcare Quality and Payment Reform. The main reason: Insurance companies pay them much less than their big city counterparts for the same services.
In Trinity, Texas, about 90 miles north of Houston, Midcoast Medical Center recently had to close its doors.
"It has a huge impact on the community. We will lose lives. Four hundred people a month come here," Marjory Pulvino, who runs the hospital's board, told CBS News.
In the East Texas Piney Woods, Midcoast was more than a building. It was a lifeline where babies were born and where the heart of Cathy Courtney's 90-year-old husband was restarted, saving his life.
Courtney said she and her husband had used the facility "about six times in the last 14 months."
Midcoast officials told CBS News the closure was driven by the same factors that have closed other rural hospitals: low reimbursement rates from elderly patients' Medicare and Medicaid coverage, which made up most of the hospital's budget.
Hospitals in urban areas, meanwhile, get significantly more reimbursement from their patients who have private insurance, which tends to pay more.
Republicans' proposed cuts to Medicaid could leave more than 8.5 million people uninsured, according to the Congressional Budget Office, and force even more rural hospitals to close.
The Center for Healthcare Quality and Payment Reform's report found that 742 rural hospitals are at risk of closing, with over 300 of those being classified as being at "immediate risk."
Courtney's husband is now home and doing well, but the 87-year-old said she worries that if there's another emergency, they won't make it to the nearest hospital now that Midcoast is closed.
While Midcoast was a 10-minute drive, the closest medical center is now more than half an hour away, Courtney said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News24
19 minutes ago
- News24
Twice-a-year R500k HIV prevention shot wins US approval
Gilead Sciences said it won US approval for a drug to prevent HIV that only has to be given twice a year, making it a convenient new way to ward off infection in a wide range of people. In two big international studies published last year, the medicine demonstrated a powerful ability to avert HIV infection. With no vaccine on the horizon, the ultra-long acting shot has been hailed by activists as perhaps the best tool the world has so far to wipe out the virus. The medicine will be marketed as Yeztugo, Gilead said, and will have a list price of $28 218 (R509 000) per year. That compares to a list price of about $26 400 per year for Descovy, the company's daily pill for HIV prevention. Shares of Gilead briefly jumped as much as 3.5%, their biggest gain in almost a month. The stock had risen 17% this year through Tuesday, outperforming a 2% increase in the S&P 500 index. Even as it works to make the drug a bestseller in rich countries like the US, the Foster City, California-based company will face great pressure to rapidly roll it out for poor and middle income countries that have been hit hard by HIV. 'This is a milestone moment in the decades-long fight against HIV,' Gilead Chief Executive Officer Daniel O'Day said in an emailed statement. 'We now have a way to end the HIV epidemic.' The approval and rollout of the drug will being closely watched by Wall Street, which is hoping it will provide a new source of growth to turbocharge Gilead's mature portfolio of pills for HIV and hepatitis C. It's expected to surpass $4 billion in annual sales by 2031, according to analysts surveyed by Bloomberg. It will compete with Apretude, a prevention shot from ViiV Healthcare, majority-owned by GSK Plc, that's given every other month. While the incidence of HIV has declined since its peak in the 1990s, some 1.3 million people are infected with the virus each year. Some of the highest rates of new cases occur in various countries in Africa. And while daily prevention pills work, they have downsides. People can forget to take them. Others may not want to get them because of the stigma surrounding HIV, or because they worry the pill bottle may inadvertently divulge their high-risk status. Gilead has filed for approval in numerous places, including South Africa, Brazil, Australia, Canada, the European Union, and the EU Medicines For All programme, which helps speed the review of drugs that will be used in developing countries. In one large international trial published last November in men and transgender people, the drug prevented all but two HIV cases among 2 180 people given it, a rate 96% lower than the background incidence level in that population. It was also superior to the company's old HIV prevention pill Truvada. And in June, Gilead said a trial of the shot in women and adolescent girls in Africa prevented 100% of HIV cases, a result the company said was unprecedented. Side effects include injection site reactions, which caused 1.2% of people in one study to stop taking it. Gilead already sells the same drug, lenacapavir, as a treatment for people with multidrug-resistant HIV under the brand Sunlenca.
Yahoo
an hour ago
- Yahoo
This Surprising Exercise May Be Better for Your Brain Than Walking, New Study Suggests
Reviewed by Dietitian Annie Nguyen, M.A., RDCycling was linked to a 19% lower dementia risk and 22% lower Alzheimer's risk. Active travel may boost gray matter in memory-related brain regions, like the hippocampus. Benefits of active travel persist regardless of genetics, especially for Alzheimer's is a condition that disrupts memory, cognitive abilities and the ability to perform daily tasks, and its prevalence continues to rise globally, particularly among older adults. The good news? Staying physically active in middle age may be a powerful way to lower the risk of developing dementia. Research consistently highlights the protective benefits of regular movement, though many adults still fall short of meeting recommended activity levels. One effective method to boost physical activity is what is referred to as 'active travel,' which includes walking or cycling for transportation. In other words, the simple act of skipping the car, bus or train and traveling by foot or bike may have a profound impact on brain health. Active travel not only promotes general health but has also been linked to a decreased risk of conditions like diabetes and potentially dementia. But participating in active travel won't be a magic bullet to living a dementia-free life. The interplay between lifestyle habits and genetic predisposition of developing dementia adds another layer of complexity. While active travel presents health advantages for most individuals, the extent of those benefits may differ depending on a person's genetic risk for dementia. To explore this relationship further, researchers in the UK conducted a study to determine how various modes of travel influence dementia risk, including Alzheimer's disease, alongside changes in brain structure, and their results were published in JAMA Network Open. To conduct this study, researchers used data from the UK Biobank cohort. These participants came from different regions across England, Scotland and Wales. The study gathered extensive information about their demographics, lifestyles, health conditions and more through surveys and exams. For this research, some participants were excluded, such as those already diagnosed with dementia at the start or shortly after (within 2 years), those who couldn't walk, and those missing travel-related data. The study looked at two groups of dementia cases: those who developed dementia before age 65 (younger onset dementia) and those diagnosed at 65 or older (later onset dementia). The researchers ultimately evaluated 479,723 participants with over 13 years of follow-up. To gather information about travel habits, participants were asked to fill out a questionnaire that included questions about transportation choices that they used. Based on their answers, the researchers grouped travel modes into four categories: nonactive (using cars, motor vehicles, or public transport), walking, mixed-walking (a mix of walking and nonactive modes) and cycling and mixed-cycling (cycling combined with other modes). To identify individuals with dementia, they relied on detailed health records using standardized codes for medical diagnoses. They also used information from magnetic resonance imaging (MRI) scans of the brain, heart and abdomen. The research also looked at genetic factors related to dementia, focusing on the APOE gene, which is known to play a key role in dementia risk. Specifically, two genetic markers (called single-nucleotide polymorphisms) were used to determine whether a participant had a higher genetic risk. Participants were then grouped based on whether or not they carried the APOE ε4 gene variant. Over a follow-up period of about 13 years, researchers found that out of all participants, 1.8% were diagnosed with dementia, including a very small group who developed it at a younger age (0.2%). The study compared different types of travel, like walking, cycling, or a mix of the two, with nonactive travel modes like driving. The results showed that people who cycled, or combined cycling with other modes, had a notably lower risk of developing dementia overall, particularly later-life dementia. For instance, using a mix of walking reduced overall dementia risk by 6%, while cycling or combining cycling with other methods lowered the risk by 19%. Even for younger onset dementia specifically, cycling or mixed-cycling appeared to cut the risk by 40%. On the other hand, walking alone seemed to slightly increase the risk of Alzheimer's disease by 14%, but cycling or mixed-cycling helped reduce its risk by 22%. When researchers studied brain scans , they found that cycling and combining cycling with other methods of travel were linked to slight increases in gray matter volume (GMV) in certain parts of the brain, including the hippocampus, which is important for memory. Walking and combining walking with other travel modes, however, were linked to slightly smaller volumes of gray and white matter in some areas. Importantly, these changes don't suggest a higher risk of dementia but highlight how different activities may affect the brain. Nonactive travel, like driving, didn't show any significant impact on brain structure in this study. Interestingly, the researchers found that genetic risk didn't change the link between travel mode and early-onset dementia or Alzheimer's disease. However, for all dementia types and late-onset dementia, genetics did play a role. People who didn't have a specific genetic marker (APOE ε4) seemed to benefit more from cycling, showing lower dementia risks compared to those with the marker. While these results are interesting and compelling, it is worth noting some limitations to this study. First, because younger onset dementia is relatively rare, the researchers couldn't break down the different types of cycling, making it hard to draw a firm conclusion. To improve this, future studies need more participants with younger onset dementia and longer follow-up periods. Second, they relied on people reporting their own travel habits, which might not always be accurate. Third, the researchers didn't track how travel habits changed over time, making it challenging to best understand these patterns. Finally, the study group lacked racial and ethnic diversity, as most participants were of European ancestry, so the results may not apply to all groups equally. Understanding how active travel impacts dementia risk can ignite meaningful changes in your daily life, especially if you are focused on supporting your cognitive health. Imagine replacing those quick car rides with a refreshing walk or bike ride! Not only do you help the environment by cutting down on emissions when you do this, but you also take a proactive step toward protecting your brain health. Whether it's walking to the corner store, cycling to work or enjoying a peaceful stroll in the park, these simple shifts can deliver long-term benefits. The great thing is that incorporating more movement into your routine is achievable for most people and it may also support your brain health to boot. Not all communities make it easy to bike or walk to work or while running errands. But if you can find time to go for a ride around the neighborhood or lengthen your parking lot walks at the grocery store, those little moments of extra activity could be helpful to your longterm health. But active travel is just one piece of the bigger picture. Brain health thrives on a combination of regular exercise, a balanced diet, staying socially connected and getting quality sleep. While we can't control genetic factors, adopting healthy habits like active travel empowers us to take charge of what we can. The key is to tailor these efforts to your environment—whether that's walking more in pedestrian-friendly cities or cycling in bike-supportive areas. Small, consistent actions add up, and over time, they may help support not only your cognitive health but your overall health as well. This study published in JAMA Network Open suggests that cycling may be linked to a 19% lower risk of developing dementia and a 22% lower risk of Alzheimer's disease. Researchers found that cycling may increase gray matter volume in the hippocampus, which plays a critical role in memory. Conversely, nonactive modes of travel like driving did not show meaningful effects on brain health. While genetic factors can influence these outcomes, the study suggests that physical activity through active travel offers protective benefits regardless of genetic predispositions, especially for those without high-risk genetic markers. Whether through cycling, walking or other forms of active travel, making intentional choices about how we move through the world can yield profound health benefits. While active travel is not a one-size-fits-all solution, it can be a practical and rewarding way to support both brain and body. By combining movement with other healthy lifestyle choices, like eating a nutrient-rich diet, getting quality sleep and staying socially connected, you can take meaningful steps toward a healthier future. Read the original article on EATINGWELL
Yahoo
an hour ago
- Yahoo
After Plummeting 40%, Where Will UnitedHealth Group Stock Be in 1 Year? Here Is What History Suggests.
UnitedHealth is facing some reputational damage following a series of missteps by the company's management. Its recent share price action is similar to what happened with CrowdStrike last year following a faulty software update in the cybersecurity platform. Historical trends show a clear indication of where beaten-down stocks of quality businesses tend to move over time. 10 stocks we like better than UnitedHealth Group › UnitedHealth Group (NYSE: UNH) has been one of the more interesting case studies in the stock market this year. Many stocks that have witnessed plummeting share prices can point to President Donald Trump's new tariff policies as the culprit. UnitedHealth's 40% decline can be traced to a number of different hiccups, but perhaps ironically, tariff rhetoric hasn't made a direct impact on the company. Let's explore what's going on at UnitedHealth right now and dig into the details on what's driving investors to run for the hills. From there, I'll draw some parallels from other businesses that remind me of UnitedHealth's current situation to help asses where the stock could be one year from now. Over the last month, UnitedHealth investors have received a lot of not-so-great information. For starters, management surprised investors when the company reduced earnings guidance during the first-quarter financial report. Not only is lowering guidance usually met with some level of panic, but the underlying reasons for the decelerating earnings likely caused some investors to seriously question the company's leadership. Essentially, management admitted that forecasts for utilization rates in its Medicare Advantage business as well as reimbursements from its pharmacy benefit management unit weren't anywhere close to reality. The cherry on top of this news was that UnitedHealth CEO Andrew Witty abruptly stepped down and was replaced with its prior chief executive, Stephen Hemsley. I know the details above make it sound like UnitedHealth Group is in a messy situation with no light at the end of the tunnel. But I can't help but draw some parallels between UnitedHealth's situation and that of another market leader, cybersecurity company CrowdStrike. CrowdStrike stock plummeted last July following the discovery of a bug in its software during an update. The ripple effect was that many of CrowdStrike's users experienced widespread outages -- impacting their own operations and customers. At the time, this was a reputational nightmare for CrowdStrike. However, as the chart above shows, CrowdStrike stock is now 113% higher than where it bottomed last July (about one year ago). To be fair, the CrowdStrike example detailed above isn't entirely an apples-to-apples comparison to UnitedHealth. Both companies operate in entirely different end markets. But at a high level, I'd argue both CrowdStrike and UnitedHealth are in the business of selling mission-critical products that are always in demand: cybersecurity and insurance. Taking my analysis one step further, notice what UnitedHealth Group stock shares with the broader price movement of the S&P 500. Over a long time horizon, both the S&P 500 index and UnitedHealth stock increased in value. These trends underscore the idea that even though businesses experience headwinds from time to time, prices continue to rise for quality businesses despite these challenges. Between the CrowdStrike example explored above and the broader movements across the S&P 500, I think that history suggests UnitedHealth Group will move higher in the long run. With that said, I am cautiously optimistic that shares will be much higher in just one year and rebound in a similar fashion to that of CrowdStrike. As the chart above illustrates, UnitedHealth stock is now trading near five-year lows. Similar to what happened with CrowdStrike, I think this price action suggests that expectations around the company's performance are exceedingly low. While 2025 won't be the best year for UnitedHealth from a growth perspective, management anticipates overcoming operational hurdles currently plaguing the company and achieving renewed growth by next year. When you combine the encouraging outlook with the flurry of insiders buying UnitedHealth stock right now, it could be argued that the bad news is already priced in. In my view, if UnitedHealth begins to show any hint of a turnaround, investors could begin pouring back into the stock. As patient investors experienced with CrowdStrike, investing in UnitedHealth stock at its current levels could pay off big time. For these reasons, I think now is a compelling opportunity to buy the dip in UnitedHealth stock and prepare to hold on as the company works through its challenges. Before you buy stock in UnitedHealth Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and UnitedHealth Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $660,821!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $886,880!* Now, it's worth noting Stock Advisor's total average return is 791% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Adam Spatacco has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CrowdStrike. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy. After Plummeting 40%, Where Will UnitedHealth Group Stock Be in 1 Year? Here Is What History Suggests. was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
